Skip to main content

Table 3 Clinical Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) used in the calibration.

From: Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action

Drug Dose Time (weeks) ADAS-Cog Effect Drug Dose Time (weeks) ADAS-Cog Effect
Placebo 0 12 0.27 Galantamine 16 26 -1.10
Placebo 0 26 1.87 Galantamine 16 52 1.49
Placebo 0 52 5.07 Galantamine 24 12 -1.96
Placebo 0 78 7.10 Galantamine 24 26 -1.10
Donepezil 5 12 -1.77 Galantamine 24 52 1.49
Donepezil 5 26 -0.27 Rivastigmine 6 12 -0.66
Donepezil 5 52 2.87 Rivastigmine 6 26 0.70
Donepezil 10 12 -2.12 Rivastigmine 6 52 3.71
Donepezil 10 26 -0.64 Rivastigmine 12 12 -1.82
Donepezil 10 52 2.48 Rivastigmine 12 26 -0.77
Galantamine 8 12 -1.77 Rivastigmine 12 52 2.01
Galantamine 8 26 -0.95 SB-742457 5 26 -0.22
Galantamine 8 52 1.29 SB-742457 15 26 -0.66
Galantamine 16 12 -1.96 SB-742457 35 26 -1.12
  1. Clinical ADAS-Cog changes for different drugs, doses and time points, used in the calibration of the AD network model. The values are derived from the population kinetic model based upon a meta-analysis and other reports on placebo and 5-HT6 antagonists.